Terms: = Chronic Myelogenous Leukemia AND BCR, FLJ16453, 613, ENSG00000186716, BCR1, D22S662, D22S11, CML, P11274, PHL, ALL AND Clinical Outcome
148 results:
1. bcr::ABL1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C; Valk PJM; Blijlevens NMA; Cornelissen JJ; Dinmohamed AG; Geelen I; Hoogendoorn M; Janssen JJWM; Daenen LGM; Reijden BAV; Westerweel PE
Eur J Haematol; 2023 Dec; 111(6):938-945. PubMed ID: 37731314
[TBL] [Abstract] [Full Text] [Related]
2. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
Yin L; Xu J; Wu W; Niu M; Li Z; Zhu F; Xu K
Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
[TBL] [Abstract] [Full Text] [Related]
3. [Current management and new treatment strategies of chronic myeloid leukemia].
Crysandt M; Brümmendorf TH
Dtsch Med Wochenschr; 2023 Jun; 148(12):744-751. PubMed ID: 37257476
[TBL] [Abstract] [Full Text] [Related]
4. Estimating prognostic relevant cutoff values for a multiplex PCR detecting bcr::ABL1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.
Hailu S; Kinde S; Cross M; Tsegaye A; Kelemu T; Seifu D; Alemayehu D; Tarekegn A; Jabessa G; Abeje D; Abebe M; Sherif A; Tadesse F; Platzbecker U; Howe R; Gebremedhin A
Ann Hematol; 2023 Jul; 102(7):1723-1729. PubMed ID: 37212909
[TBL] [Abstract] [Full Text] [Related]
5. B-Lymphoid Blast Phase-chronic Myeloid leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract] [Full Text] [Related]
6. chronic disease management practices and factors associated with health-related quality-of-life for persons with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
Zhang Q; Li Z; Hou Y; Dang H; Chen J; Liang L; Wang Q; Cao C; Zhao H; Gui R; Zu Y; Zhou J; Yu F; Wang J; Song Y; Zhang Y
Ann Palliat Med; 2022 Apr; 11(4):1336-1350. PubMed ID: 35523742
[TBL] [Abstract] [Full Text] [Related]
7. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival.
Guru SA; Sumi MP; Mir R; Beg MMA; Koner BC; Saxena A
BMC Cancer; 2022 Apr; 22(1):405. PubMed ID: 35421941
[TBL] [Abstract] [Full Text] [Related]
8. Assessment of Imatinib as a Primary Treatment of chronic Myeloid leukemia in chronic Phase: a Cohort Study.
Merin D; Krishna A; Jayakumar S; Mahima A; Anila KN; Sidharthan N
J Oncol Pharm Pract; 2023 Apr; 29(3):547-556. PubMed ID: 35048760
[TBL] [Abstract] [Full Text] [Related]
9. Adverse outcomes in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: Follow-up of patients diagnosed 2002-2017 in a complete coverage and nationwide agnostic register study.
Dahlén T; Edgren G; Ljungman P; Flygt H; Richter J; Olsson-Strömberg U; Wadenvik H; Dreimane A; Myhr-Eriksson K; Zhao J; Själander A; Höglund M; Stenke L
Am J Hematol; 2022 Apr; 97(4):421-430. PubMed ID: 35015312
[TBL] [Abstract] [Full Text] [Related]
10. Assessment of quantitative polymerase chain reaction for bcr-ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
Dominy KM; Claudiani S; O'Hare M; Szydlo R; Gerrard G; Foskett P; Foroni L; Milojkovic D; Apperley JF; Khorashad J
Br J Haematol; 2022 Apr; 197(1):52-62. PubMed ID: 34997766
[TBL] [Abstract] [Full Text] [Related]
11.
Egeli DB; Hanfstein B; Lauseker M; Pfirrmann M; Saussele S; Baerlocher GM; Müller MC
Leuk Lymphoma; 2022 Apr; 63(4):955-962. PubMed ID: 34872441
[TBL] [Abstract] [Full Text] [Related]
12. [chronic myeloid leukemia with an in-frame exon 4 deletion in ABL1 with acute abdomen due to an intrapelvic bulky mass as the initial symptom].
Ide A; Tokunaga M; Yoshikawa S; Kondo A; Nishiura N; Inoue S; Morita T; Tominaga N; Maeda T
Rinsho Ketsueki; 2021; 62(11):1615-1622. PubMed ID: 34866085
[TBL] [Abstract] [Full Text] [Related]
13. Simvastatin potentiates the cell-killing activity of imatinib in imatinib-resistant chronic myeloid leukemia cells mainly through PI3K/AKT pathway attenuation and Myc downregulation.
Ding L; Chen Q; Chen K; Jiang Y; Li G; Chen Q; Bai D; Gao D; Deng M; Zhang H; Xu B
Eur J Pharmacol; 2021 Dec; 913():174633. PubMed ID: 34843676
[TBL] [Abstract] [Full Text] [Related]
14. clinical outcome of chronic myeloid leukemia patients who switch from first-line therapy with a second generation tyrosine kinase inhibitor to an alternative TKI.
Ma CE; Ghosh S; Leyshon C; Blosser N; Dersch-Mills D; Jupp J; Savoie L; Liew E; Jamani K
Leuk Res; 2021 Dec; 111():106674. PubMed ID: 34333277
[TBL] [Abstract] [Full Text] [Related]
15. Successful tyrosine kinase inhibitor discontinuation outside clinical trials - data from the population-based Swedish chronic myeloid leukaemia registry.
Flygt H; Sandin F; Dahlén T; Dremaine A; Lübking A; Markevärn B; Myhr-Eriksson K; Olsson K; Olsson-Strömberg U; Själander A; Söderlund S; Wennström L; Wadenvik H; Stenke L; Höglund M; Richter J
Br J Haematol; 2021 Jun; 193(5):915-921. PubMed ID: 33782950
[TBL] [Abstract] [Full Text] [Related]
16. Evaluation of cytogenetic response in cml patients with variant Philadelphia translocation.
Shetty D; Talker E; Jain H; Talker J; Patkar N; Subramanian P; Jain H; Bonda A; Punatar S; Gokarn A; Bagal B; Sengar M; Khattry N
Asia Pac J Clin Oncol; 2022 Feb; 18(1):99-108. PubMed ID: 33629824
[TBL] [Abstract] [Full Text] [Related]
17. Megakaryocytic Clustering in chronic Myeloid leukemia: Can it be a Predictor of clinical outcome?
Mughal Z; Babar H; Ashraf S; Hamid A; Khokhar A; Qamar S
J Coll Physicians Surg Pak; 2021 Jan; 31(1):34-38. PubMed ID: 33546530
[TBL] [Abstract] [Full Text] [Related]
18. Whole exome sequencing identifies a novel FANCD2 gene splice site mutation associated with disease progression in chronic myeloid leukemia: Implication in targeted therapy of advanced phase cml.
Absar M; Mahmood A; Akhtar T; Basit S; Ramzan K; Jameel A; Afzal S; Ullah A; Qureshi K; Alanazi N; Iqbal Z
Pak J Pharm Sci; 2020 May; 33(3(Special)):1419-1426. PubMed ID: 33361032
[TBL] [Abstract] [Full Text] [Related]
19. Why is it critical to achieve a deep molecular response in chronic myeloid leukemia?
Branford S
Haematologica; 2020 Dec; 105(12):2730-2737. PubMed ID: 33054104
[TBL] [Abstract] [Full Text] [Related]
20. Players in Drug-Resistant leukemia Stem/Initiating Cells and Immunity in Patients with cml in Context of Oxygen Levels: Would Collecting/Processing Cells in Hypoxia Offer Additional Information? A Next Frontier of Investigation.
Broxmeyer H
Blood Cancer Discov; 2020 Jul; 1(1):13-15. PubMed ID: 34661136
[TBL] [Abstract] [Full Text] [Related]
[Next]
